Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DC-based immunotherapy of B-cell malignancies.

V L Reichardt1, Peter Brossart

  • 1Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.

Cytotherapy
|February 27, 2004
PubMed
Summary

This review explores dendritic cell (DC)-based immunotherapy for B-cell malignancies. DC vaccination shows promise for treating follicular lymphoma, multiple myeloma, and other B-cell cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells.

International journal of molecular sciences·2026
Same author

Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma.

Cancer treatment reviews·2026
Same author

Longer time to response in hemato-oncological patients with immune thrombocytopenia (ITP): a pilot study.

Expert review of hematology·2026
Same author

Hypomethylating Agents and Venetoclax Based Triplets Targeting FLT3, IDH and KMT2A in Acute Myeloid Leukemia: Current Studies and Challenges of a Tailored Approach.

Cancers·2026
Same author

NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Nature communications·2025
Same author

Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial.

European journal of haematology·2025

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • B-cell malignancies are fatal diseases requiring novel therapeutic strategies.
  • Vaccination protocols aim to enhance anti-tumor immune responses.
  • Dendritic cell (DC)-based immunotherapy utilizes antigen-presenting cells (APCs) for targeted immune activation.

Purpose of the Study:

  • To review the current experience with DC-based immunotherapy in B-cell malignancies.
  • To discuss clinical trials and preclinical findings in various B-cell cancers.
  • To explore future perspectives for DC vaccination in these diseases.

Main Methods:

  • Review of published clinical trials in follicular non-Hodgkin lymphoma (NHL) and multiple myeloma.
  • Analysis of preclinical data for chronic lymphocytic leukemia (CLL) and Waldenström's macroglobulinemia.
  • Synthesis of existing data to inform future DC vaccination strategies.

Main Results:

  • DC-based immunotherapy has been investigated in follicular NHL and multiple myeloma through clinical trials.
  • Preclinical studies show potential for DC vaccination in CLL and Waldenström's macroglobulinemia.
  • Experience highlights the role of DCs as powerful APCs in anti-cancer immunity.

Conclusions:

  • DC-based immunotherapy represents a promising therapeutic avenue for B-cell malignancies.
  • Further research and clinical trials are warranted to optimize DC vaccination protocols.
  • DC vaccination holds potential for improving outcomes in patients with B-cell cancers.

Related Experiment Videos